ABSTRACT
Objective To explore the value of delay alternating with nutation for tailored excitation (DANTE)- sampling perfection with application optimized contrast using different flip-angle evolution (SPACE) sequences in quantitative evaluation of arachnoid granules (AG). Methods Thirty patients with arachnoid granules confirmed by conventional imaging were enrolled. All patients underwent SPACE and DANTE-SPACE sequences scanning. Distribution characteristics of arachnoid particles in sinus cavities and cranial plate on SPACE and DANTE-SPACE sequence images were evaluated, and the measurements were performed and statistically analyzed, including maximum cross-sectional area, longest diameter, SNR and CNR. Results A total of 43 arachnoid particles were detected with SPACE sequence, 29 in the sinus cavities and 14 in the cranial plate, while 45 arachnoid particles were found with DANTE-SPACE, 31 in the sinus cavities and 14 in the cranial plate. SPACE and DANTE-SPACE sequences showed no statistically significant difference in distribution of arachnoid particles (χ2=0.155, P=0.997). In the sinus cavity, SPACE and DANTE-SPACE sequences showed significant differences of the maximum cross-sectional area ([32.55±17.08]mm2, [29.15±16.24]mm2), the longest diameter ([7.13±2.00]mm, [6.42±1.81]mm), SNR (88.82±29.57, 83.30±32.11) and CNR (45.99±28.57, 65.33±30.96) of arachnoid particles (all P0.05). Conclusion DANTE-SPACE can effectively inhibit slow blood flow artifacts in the sinus, and accurately display arachnoid particles.
ABSTRACT
El cáncer de mama es uno de los principales problemas de salud y, aproximadamente, 10% de los casos son de origen genético. En un estudio previo realizado por nosotros, se encontraron mutaciones fundadoras en los genes BRCA1 y BRCA2; esto permite trazar estrategias de detección temprana para personas con alta susceptibilidad en Colombia e implementar medidas profilácticas. El objetivo de este estudio fue estimar el componente genético del cáncer de mama en Colombia, mediante el estudio de la frecuencia y penetrancia de las mutaciones germinales en BRCA1 y BRCA2. Se estudiaron 766 pacientes que cumplieron el criterio de habérseles diagnosticado cáncer de mama después de 2004 y se realizaron estudios moleculares para las mutaciones fundadoras. Se entregaron los resultados a las pacientes y se analizaron los datos para frecuencia y penetrancia. La frecuencia total para mutaciones fundadoras para BRCA1 y BRCA2 fue de 4,2% (IC95% 2,9-5,8), y la penetrancia a los 50 años fue de 33,3 (IC95% 15,2-63,1) para BRCA1 y de 32 (IC95%11,8-70,9) para BRCA2 La alta frecuencia de mutaciones justifica la necesidad de ofrecer este tipo de examen a mujeres con cáncer de mama, independientemente de los antecedentes.Es necesario ampliar los estudios para realizar cálculos de penetrancia a los 70 años...
Breast cancer is one of the main public health problems, approximately 10% are genetic. In a previous study carried out by our group, founder mutations in BRCA1 and BRCA2 genes were detected; this will allow early testing and detection of patients with high breast and ovarian cancer susceptibility in Colombia, and to implement prophylactic strategies. The aim of this study was to estimate the genetic component of breast cancer in Colombia, testing for the frequency and penetrance of germinal mutations in BRCA1 and BRCA2. 766 patients fulfilling the criteria of breast cancer diagnosis after 2004 were studied for founder mutations. The results were reported to the patients; frequency and penetrance were tested. Total frequency for founder mutations in BRCA1 and BRCA2 was 4.2% (CI 95%: 2.9-5.8), and penetrance at 50 years was 33, 3(CI 95%: 15.2 - 63.1) for BRCA1 and 32(CI 95%:11.8 - 70.9) for BRCA2. The high frequency of the mutations supports the need to implement genetic testing policy for patients with breast cancer independently of family history or age. It is necessary to continue the study to perform penetrance testing at the 70 year limit...